SCHEMBL2809802

SCHEMBL2809802

O=C(N[C@@]1(C(=O)NCc2ccc(Nc3ccccc3C(F)(F)F)cc2)CCOC1)c1cccc(Cl)n1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.35
LMNA P02545 1/20 0.35
P2RX7 Q99572 3/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
AURKA O14965 1/20 0.34
CNR2 P34972 2/20 0.34
MYC P01106 1/20 0.34
MAX P61244 1/20 0.34
HTT P42858 2/20 0.34
EPHX2 P34913 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPK8 P45983 1/20 0.33
MAPK10 P53779 1/20 0.33
BDKRB1 P46663 1/20 0.33
USP36 Q9P275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808601 0.91 CTDSP1 (0.35) P2RX7CTDSP1AURKAMYCMAX
SCHEMBL13128480 0.90 CTDSP1 (0.35) CTDSP1AURKACNR2MYCMAX
SCHEMBL185068 0.88 P2RX7 (0.34) LMNAP2RX7CTDSP1AURKACNR2
SCHEMBL13128481 0.87 CTDSP1 (0.35) P2RX7CTDSP1AURKAMYCMAX
SCHEMBL13128509 0.85 CTDSP1 (0.35) CTDSP1AURKAMYCMAXHTT
SCHEMBL2806967 0.84 AURKA (0.39) LMNAP2RX7CTDSP1AURKACNR2
SCHEMBL2806970 0.84 AURKA (0.39) LMNAP2RX7CTDSP1AURKACNR2
SCHEMBL2809658 0.84 CYP1A2 (0.39) AURKATRPV1ALDH1A1MAPTHPGD
SCHEMBL2811096 0.83 NAMPT (0.41) AURKAMYCMAXTRPV1BDKRB1
SCHEMBL2811098 0.83 NAMPT (0.41) AURKAMYCMAXTRPV1BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 IDO1 3069/4885LMNA 2613/4885P2RX7 30/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 IDO1 3069/4885LMNA 2613/4885P2RX7 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.